Market Place
Sourcing Support
Innate Pharma Secures $7.9M for IPH6501 Follicular Lymphoma Study
05 Dec 2024 //
BUSINESSWIRE
Innate Pharma Highlights ASH 2024 Abstracts
02 Dec 2024 //
BUSINESSWIRE
Innate Pharma Releases Its 2025 Financial Calendar
20 Nov 2024 //
BUSINESSWIRE
Innate Publishes Next-Gen ANKET® IPH6501 Data in Science Immunology
19 Nov 2024 //
BUSINESSWIRE
Innate antibody pits NK cells against lymphoma in animal models
15 Nov 2024 //
FIERCE BIOTECH
Innate Pharma Reports Q3 2024 Business Update & Financial Results
13 Nov 2024 //
BUSINESSWIRE
Innate Pharma Announces Q3 2024 Results & Conference Call
07 Nov 2024 //
BUSINESSWIRE
Innate Pharma To Participate In Upcoming Investor Conferences
29 Oct 2024 //
BUSINESSWIRE
Innate Pharma Participate in Upcoming Investor Conferences
29 Oct 2024 //
BUSINESSWIRE
Innate Pharma Appoints Jonathan Dickinson As New CEO
14 Oct 2024 //
BUSINESSWIRE
Innate Pharma Hosts KOL Symposium On Immunotherapy, Oct 3
30 Sep 2024 //
BUSINESSWIRE
Innate Pharma Announces FDA Clearance Of IND For Solid Tumors
23 Sep 2024 //
BUSINESSWIRE
Innate Pharma Reports First Half 2024 Business Update and Financial Results
12 Sep 2024 //
BUSINESSWIRE
Innate Pharma: Monalizumab Data From NeoCOAST-2 Presented At WCLC 2024
09 Sep 2024 //
BUSINESSWIRE
Innate Pharma Announces Call and Webcast for H1 2024 Financial Results
05 Sep 2024 //
BUSINESSWIRE
Innate Pharma to Participate in H.C. Wainwright Annual Investment Conference
04 Sep 2024 //
BUSINESSWIRE
Innate Pharma Announces Its Participation in Upcoming Investor Conference
31 Jul 2024 //
BUSINESSWIRE
Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024
24 Jul 2024 //
BUSINESSWIRE
Innate Pharma Updates Sanofi`s SAR443579 IPH6101 Cancer Trial
18 Jun 2024 //
PHARMABIZ
Innate Pharma Shares Results From Sanofi`s Blood Cancer Phase 1/2 Trial
17 Jun 2024 //
BUSINESSWIRE
Innate Pharma: Positive Phase 2 Lacutamab Data In Mycosis Fungoides
04 Jun 2024 //
BUSINESSWIRE
Innate Pharma Announces Its Participation in Upcoming Investor Conferences
28 May 2024 //
BUSINESSWIRE
Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
24 May 2024 //
BUSINESSWIRE
Outcome of Innate Pharma’s 2024 Annual General Meeting
23 May 2024 //
BUSINESSWIRE
Innate Pharma: Clarification Regarding SAR443579 Designation
21 May 2024 //
BUSINESSWIRE
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
15 May 2024 //
BUSINESSWIRE
Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
13 May 2024 //
BUSINESSWIRE
Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
07 May 2024 //
BUSINESSWIRE
Innate: Sanofi NK Engager SAR443579 Advances To Phase 2
15 Apr 2024 //
BUSINESSWIRE
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
15 Apr 2024 //
BUSINESSWIRE
Innate Pharma Presents IPH45 Pre-IND Efficacy at AACR 2024
10 Apr 2024 //
BUSINESSWIRE
Innate Files Its 2023 Universal Registration Document & 2023 Annual Report
05 Apr 2024 //
BUSINESSWIRE
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
20 Mar 2024 //
BUSINESSWIRE
Innate Pharma Announces Conference Call for Full Year 2023 Financial Results
14 Mar 2024 //
BUSINESSWIRE
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data
06 Mar 2024 //
BUSINESSWIRE
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501
06 Mar 2024 //
BUSINESSWIRE
Innate Pharma Announces Its Participation to Upcoming Investor Conference
21 Feb 2024 //
BUSINESSWIRE
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024
12 Jan 2024 //
BUSINESSWIRE
Innate Pharma Strengthens Leadership
04 Jan 2024 //
BUSINESSWIRE
Innate Pharma Announces U.S. FDA Lifts Partial Hold on Lacutamab Program
04 Jan 2024 //
BUSINESSWIRE
Innate Announces Licensing of a Fourth Natural Killer Cell Engager to Sanofi
19 Dec 2023 //
BUSINESSWIRE
Innate Pharma Announces Leadership Change
18 Dec 2023 //
BUSINESSWIRE
Innate Shares Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101
11 Dec 2023 //
BUSINESSWIRE
Innate Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab
10 Dec 2023 //
BUSINESSWIRE
Innate Pharma to Host Virtual KOL Event on Lacutamab
27 Nov 2023 //
BUSINESSWIRE
Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update
13 Nov 2023 //
BUSINESSWIRE
Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update
07 Nov 2023 //
BUSINESSWIRE
Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101
03 Nov 2023 //
BUSINESSWIRE
Innate Pharma Announces Its Participation to Upcoming Investor Conferences
27 Oct 2023 //
BUSINESSWIRE
Innate Pharma 2024 Financial Calendar
19 Oct 2023 //
BUSINESSWIRE
Innate Pharma Announces Abstracts Selected for ESMO Congress 2023
16 Oct 2023 //
BUSINESSWIRE
Innate lymphoma trials put on partial hold after patient dies
06 Oct 2023 //
FIERCE BIOTECH
Innate Pharma Announces Presentation of Interim Results of Ph 2 TELLOMAK Study
22 Sep 2023 //
BUSINESSWIRE
Innate Pharma Reports First Half 2023 Financial Results and Business Update
13 Sep 2023 //
BUSINESSWIRE
Innate Pharma Announces Its Participation toUpcoming Conferences First Half 2023
28 Aug 2023 //
BUSINESSWIRE
Innate Pharma to Participate in Upcoming Investor Conference
10 Aug 2023 //
BUSINESSWIRE
First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Trial in RRMM
11 Jul 2023 //
BUSINESSWIRE
Innate doses first patient in study of combo therapy for lung cancer
27 Jun 2023 //
CLINICAL TRIALS ARENA
First Patient Dosed in Ph2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
26 Jun 2023 //
BUSINESSWIRE
Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab
12 Jun 2023 //
BUSINESSWIRE
